Natco Pharma Limited Share Price & Analysis
₹961.9▲ +1.18%Updated 21 Jul 2026, 05:01 pm IST
LTP
₹961.9
+1.18%
Open
₹—
High
₹965.1
Low
₹948.25
Close
₹961.9
52W High
₹1,227
52W Low
₹789
Volume
316K
Lot Size
1
Sector
Healthcare
Market Cap
₹17K Cr
Face Value
₹2
Mid CapNIFTY 500SMALLCAP 100
Price Chart
Fundamentals
P/E
11.9
Sector P/E
54.4
P/B
1.95
EPS
₹79.24
ROE
16.9%
ROCE
17.1%
D/E Ratio
0.08
Div Yield
0.63%
Book Value
₹515
+
Strengths
- ✓Strong return on equity (ROE 16.9%)
- ✓Efficient capital deployment (ROCE 17.1%)
- ✓Attractively valued vs sector (P/E 11.9x vs industry 54.4x)
- ✓Virtually debt-free
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,944 | ₹4.6L Cr | 37.3 | 5.59 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹7,388 | ₹1.9L Cr | 73.4 | 11.71 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹5,040 | ₹1.6L Cr | 73.6 | 20.32 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,939 | ₹1.3L Cr | 64.9 | 13.56 | 22.1 | 17.9 | 0.88 |
| CIPLA Cipla Limited | ₹1,416 | ₹1.1L Cr | 30.1 | 3.32 | 11.6 | 15.5 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,123 | ₹1.1L Cr | 21 | 4.17 | 21.2 | 21.1 | 0.38 |
| LUPIN Lupin Limited | ₹2,405 | ₹1.1L Cr | 19.6 | 4.9 | 28.7 | 29.9 | 0.32 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
NATCOPHARM · as of Mar 2026
Promoters49.56%▼0.06
FII17.49%▼0.45
DII5.64%▲0.05
Public27.30%▲0.42
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 49.71% | 49.71% | 49.71% | 49.62% | 49.62% | 49.56% |
| FII | 13.72% | 16.14% | 17.45% | 17.51% | 17.94% | 17.49% |
| DII | 11.26% | 9.69% | 7.86% | 6.75% | 5.59% | 5.64% |
| Public | 25.32% | 24.46% | 24.99% | 26.13% | 26.88% | 27.30% |
Corporate Events
Interim Dividend - Rs 1.50 Per Share
Dividend17 Feb 2026
Interim Dividend - Rs 1.50 Per Share
Dividend19 Nov 2025
Interim Dividend - Rs 2 Per Share
Dividend18 Aug 2025
Interim Dividend - Rs 1.50 Per Share
Dividend17 Feb 2025
Interim Dividend - Rs 1.50 Per Share
Dividend26 Nov 2024
Annual General Meeting
AGM24 Sept 2024
Interim Dividend - Rs 3 Per Share
Dividend22 Aug 2024
Interim Dividend - Rs 1.25 Per Share
Dividend25 Feb 2024
Interim Dividend - Rs 1.25 Per Share
Dividend23 Nov 2023
Annual General Meeting
AGM24 Sept 2023
Latest News
All news →Natco Pharma announces board meeting outcomes
*Natco Pharma announces board meeting outcomes*. The company disclosed the outcomes of its recent board meeting held on July 08, 2026. No major strategic decisions or financial announcements were revealed. The update is primarily procedural in nature with no immediate business impact. 📊 *STOCKS:* NATCOPHARM | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Pharma
NSE Filing8 Jul
Natco Pharma acquires additional 13.25% stake in Adcock Ingram
*Natco Pharma acquires additional 13.25% stake in Adcock Ingram* — Natco Pharma has increased its holding in South Africa-based Adcock Ingram Holdings by acquiring an additional **13.25% stake**. This move strengthens its strategic footprint in the African pharmaceutical market. The acquisition enhances Natco’s control and potential revenue share in the joint venture. 📊 *STOCKS:* NATCOPHARM | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Acquisition
NSE Filing14 Jul
Financials
Quarterly Results
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹739 Cr ▲14.2% | ₹647 Cr ▼52.5% | ₹1.4K Cr ▲2.6% | ₹1.3K Cr ▲8.8% | ₹1.2K Cr ▲157.1% | ₹475 Cr ▼65.4% | ₹1.4K Cr ▲0.6% | ₹1.4K Cr |
| Op. Profit | ₹128 Cr ▼19.5% | ₹159 Cr ▼72.5% | ₹579 Cr ▲1.4% | ₹571 Cr ▲4.2% | ₹548 Cr ▲1305.1% | ₹39 Cr ▼95.1% | ₹804 Cr ▼0.1% | ₹805 Cr |
| OPM | 17.0% ▼32.0% | 25.0% ▼40.5% | 42.0% ▼2.3% | 43.0% ▼4.4% | 45.0% ▲462.5% | 8.0% ▼86.4% | 59.0% ▲0.0% | 59.0% |
| Net Profit | ₹269 Cr ▲78.1% | ₹151 Cr ▼70.8% | ₹518 Cr ▲7.9% | ₹480 Cr ▲18.2% | ₹406 Cr ▲207.6% | ₹132 Cr ▼80.5% | ₹676 Cr ▲1.2% | ₹668 Cr |
| EPS (₹) | 14.96 ▲76.8% | 8.46 ▼70.8% | 28.94 ▲7.8% | 26.84 ▲18.2% | 22.7 ▲205.5% | 7.43 ▼80.3% | 37.81 ▲1.3% | 37.32 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹4.1K Cr ▼7.9% | ₹4.4K Cr ▲10.8% | ₹4.0K Cr ▲47.7% | ₹2.7K Cr ▲39.2% | ₹1.9K Cr ▼5.2% | ₹2.1K Cr ▲7.2% | ₹1.9K Cr ▼8.5% | ₹2.1K Cr ▼4.2% | ₹2.2K Cr ▲8.2% | ₹2.0K Cr |
| Expenses | ₹2.6K Cr ▲18.3% | ₹2.2K Cr ▼0.5% | ₹2.2K Cr ▲26.7% | ₹1.8K Cr ▲5.4% | ₹1.7K Cr ▲16.3% | ₹1.4K Cr ▲8.6% | ₹1.3K Cr ▲2.5% | ₹1.3K Cr ▲3.5% | ₹1.3K Cr ▼6.1% | ₹1.3K Cr |
| Op. Profit | ₹1.4K Cr ▼34.6% | ₹2.2K Cr ▲25.2% | ₹1.8K Cr ▲87.4% | ₹936 Cr ▲254.5% | ₹264 Cr ▼56.4% | ₹606 Cr ▲3.9% | ₹583 Cr ▼26.7% | ₹795 Cr ▼14.3% | ₹928 Cr ▲35.9% | ₹683 Cr |
| OPM | 35.0% ▼30.0% | 50.0% ▲13.6% | 44.0% ▲25.7% | 35.0% ▲150.0% | 14.0% ▼53.3% | 30.0% ▲0.0% | 30.0% ▼21.1% | 38.0% ▼9.5% | 42.0% ▲23.5% | 34.0% |
| Other Income | ₹298 Cr ▼15.8% | ₹354 Cr ▲181.0% | ₹126 Cr ▲20.0% | ₹105 Cr ▲6.1% | ₹99 Cr ▼4.8% | ₹104 Cr ▼2.8% | ₹107 Cr ▼17.7% | ₹130 Cr ▲225.0% | ₹40 Cr ▲185.7% | ₹14 Cr |
| Interest | ₹37 Cr ▲54.2% | ₹24 Cr ▲26.3% | ₹19 Cr ▲35.7% | ₹14 Cr ▼22.2% | ₹18 Cr ▲38.5% | ₹13 Cr ▼40.9% | ₹22 Cr ▲15.8% | ₹19 Cr ▲26.7% | ₹15 Cr ▼16.7% | ₹18 Cr |
| Depreciation | ₹207 Cr ▼11.9% | ₹235 Cr ▲25.7% | ₹187 Cr ▲14.0% | ₹164 Cr ▲14.7% | ₹143 Cr ▲22.2% | ₹117 Cr ▲17.0% | ₹100 Cr ▲23.5% | ₹81 Cr ▲22.7% | ₹66 Cr ▲22.2% | ₹54 Cr |
| PBT | ₹1.5K Cr ▼34.9% | ₹2.3K Cr ▲36.9% | ₹1.7K Cr ▲94.2% | ₹862 Cr ▲326.7% | ₹202 Cr ▼65.2% | ₹580 Cr ▲1.9% | ₹569 Cr ▼31.0% | ₹825 Cr ▼7.0% | ₹887 Cr ▲42.1% | ₹624 Cr |
| Tax % | 8.0% ▼55.6% | 18.0% ▲5.9% | 17.0% ▲0.0% | 17.0% ▲6.3% | 16.0% ▼33.3% | 24.0% ▲26.3% | 19.0% ▼13.6% | 22.0% ▲0.0% | 22.0% ▲0.0% | 22.0% |
| Net Profit | ₹1.4K Cr ▼24.7% | ₹1.9K Cr ▲35.7% | ₹1.4K Cr ▲94.1% | ₹715 Cr ▲320.6% | ₹170 Cr ▼61.5% | ₹442 Cr ▼3.5% | ₹458 Cr ▼28.7% | ₹642 Cr ▼7.6% | ₹695 Cr ▲43.3% | ₹485 Cr |
| EPS (₹) | 79.2 ▼24.8% | 105.26 ▲35.8% | 77.51 ▲97.8% | 39.18 ▲320.8% | 9.31 ▼61.5% | 24.18 ▼4.5% | 25.31 ▼28.2% | 35.24 ▼6.6% | 37.74 ▲35.4% | 27.88 |
| Div Payout | 6.0% ▲0.0% | 6.0% ▼50.0% | 12.0% ▼14.3% | 14.0% ▼70.8% | 48.0% ▲118.2% | 22.0% ▼18.5% | 27.0% ▲50.0% | 18.0% ▼18.2% | 22.0% ▼8.3% | 24.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | ||||||||||
| Equity Capital | ₹36 Cr ▲0.0% | ₹36 Cr ▲0.0% | ₹36 Cr ▲0.0% | ₹36 Cr ▲0.0% | ₹36 Cr ▲0.0% | ₹36 Cr ▲0.0% | ₹36 Cr ▲0.0% | ₹36 Cr ▼2.7% | ₹37 Cr ▲5.7% | ₹35 Cr |
| Reserves | ₹9.2K Cr ▲21.3% | ₹7.6K Cr ▲30.2% | ₹5.8K Cr ▲20.3% | ₹4.8K Cr ▲14.4% | ₹4.2K Cr ▲3.5% | ₹4.1K Cr ▲9.3% | ₹3.7K Cr ▲8.3% | ₹3.5K Cr ▲13.7% | ₹3.0K Cr ▲88.0% | ₹1.6K Cr |
| Borrowings | ₹714 Cr ▲155.9% | ₹279 Cr ▼24.8% | ₹371 Cr ▲122.2% | ₹167 Cr ▼59.9% | ₹416 Cr ▲55.2% | ₹268 Cr ▼15.2% | ₹316 Cr ▼18.1% | ₹386 Cr ▲123.1% | ₹173 Cr ▼22.1% | ₹222 Cr |
| Other Liabilities | ₹1.1K Cr ▲53.1% | ₹744 Cr ▲9.1% | ₹682 Cr ▲10.5% | ₹617 Cr ▲43.5% | ₹430 Cr ▲6.7% | ₹403 Cr ▼19.1% | ₹498 Cr ▲16.4% | ₹428 Cr ▼8.9% | ₹470 Cr ▲5.4% | ₹446 Cr |
| Total Liabilities | ₹11.1K Cr ▲28.3% | ₹8.6K Cr ▲25.0% | ₹6.9K Cr ▲22.1% | ₹5.7K Cr ▲10.7% | ₹5.1K Cr ▲6.6% | ₹4.8K Cr ▲4.4% | ₹4.6K Cr ▲6.6% | ₹4.3K Cr ▲15.8% | ₹3.7K Cr ▲60.3% | ₹2.3K Cr |
| Assets | ||||||||||
| Fixed Assets | ₹2.8K Cr ▲3.9% | ₹2.7K Cr ▲8.3% | ₹2.5K Cr ▲2.6% | ₹2.4K Cr ▲5.0% | ₹2.3K Cr ▲14.3% | ₹2.0K Cr ▲27.7% | ₹1.6K Cr ▲29.1% | ₹1.2K Cr ▲20.4% | ₹1.0K Cr ▲22.3% | ₹833 Cr |
| CWIP | ₹294 Cr ▲30.7% | ₹225 Cr ▲64.2% | ₹137 Cr ▲114.1% | ₹64 Cr ▼50.8% | ₹130 Cr ▼41.7% | ₹223 Cr ▼56.9% | ₹518 Cr ▼18.8% | ₹638 Cr ▲32.9% | ₹480 Cr ▲42.9% | ₹336 Cr |
| Investments | ₹3.1K Cr ▲559.7% | ₹474 Cr ▼12.1% | ₹539 Cr ▲37.5% | ₹392 Cr ▲27.3% | ₹308 Cr ▲1.3% | ₹304 Cr ▲171.4% | ₹112 Cr ▼33.7% | ₹169 Cr ▲122.4% | ₹76 Cr ▲137.5% | ₹32 Cr |
| Other Assets | ₹4.8K Cr ▼7.3% | ₹5.2K Cr ▲40.0% | ₹3.7K Cr ▲34.8% | ₹2.8K Cr ▲17.5% | ₹2.4K Cr ▲5.3% | ₹2.2K Cr ▼5.5% | ₹2.4K Cr ▲4.5% | ₹2.3K Cr ▲6.1% | ₹2.1K Cr ▲91.8% | ₹1.1K Cr |
| Total Assets | ₹11.1K Cr ▲28.3% | ₹8.6K Cr ▲25.0% | ₹6.9K Cr ▲22.1% | ₹5.7K Cr ▲10.7% | ₹5.1K Cr ▲6.6% | ₹4.8K Cr ▲4.4% | ₹4.6K Cr ▲6.6% | ₹4.3K Cr ▲15.8% | ₹3.7K Cr ▲60.3% | ₹2.3K Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹1.8K Cr ▲4.2% | ₹1.7K Cr ▲40.0% | ₹1.2K Cr ▲42.8% | ₹849 Cr ▲1745.7% | ₹46 Cr ▼84.6% | ₹299 Cr ▼28.3% | ₹417 Cr ▼37.7% | ₹669 Cr ▲44.2% | ₹464 Cr ▲34.1% | ₹346 Cr |
| Investing CF | ₹-2.1K Cr ▼45.0% | ₹-1.4K Cr ▼40.0% | ₹-1.0K Cr ▼120.6% | ₹-465 Cr ▼11725.0% | ₹4 Cr ▲103.7% | ₹-107 Cr ▲38.9% | ₹-175 Cr ▲71.4% | ₹-611 Cr ▲45.3% | ₹-1.1K Cr ▼273.2% | ₹-299 Cr |
| Financing CF | ₹298 Cr ▲241.2% | ₹-211 Cr ▲14.6% | ₹-247 Cr ▲32.0% | ₹-363 Cr ▼1137.1% | ₹35 Cr ▲118.8% | ₹-186 Cr ▲25.9% | ₹-251 Cr ▼392.2% | ₹-51 Cr ▼107.8% | ₹651 Cr ▲1456.3% | ₹-48 Cr |
| Net Cash Flow | ₹-16 Cr ▼132.0% | ₹50 Cr ▲180.6% | ₹-62 Cr ▼395.2% | ₹21 Cr ▼75.3% | ₹85 Cr ▲1316.7% | ₹6 Cr ▲175.0% | ₹-8 Cr ▼214.3% | ₹7 Cr ▲450.0% | ₹-2 Cr ▼100.0% | ₹-1 Cr |
| Free Cash Flow | ₹1.4K Cr ▲6.1% | ₹1.3K Cr ▲52.0% | ₹855 Cr ▲26.9% | ₹674 Cr ▲574.6% | ₹-142 Cr ▼254.3% | ₹92 Cr ▲13.6% | ₹81 Cr ▼64.0% | ₹225 Cr ▲294.7% | ₹57 Cr ▼13.6% | ₹66 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 79d ▼23.3% | 103d ▼5.5% | 109d ▼5.2% | 115d ▼0.9% | 116d ▲58.9% | 73d ▼30.5% | 105d ▲19.3% | 88d ▼17.0% | 106d ▲23.3% | 86d |
| Inventory Days | 480d ▲18.5% | 405d ▲13.4% | 357d ▼17.4% | 432d ▼12.9% | 496d ▼13.0% | 570d ▲6.7% | 534d ▼2.0% | 545d ▲40.1% | 389d ▲82.6% | 213d |
| Days Payable | 216d ▲49.0% | 145d ▲20.8% | 120d ▼21.6% | 153d ▲45.7% | 105d ▲1.0% | 104d ▼57.4% | 244d ▲8.9% | 224d ▼6.3% | 239d ▲49.4% | 160d |
| Cash Conv. Cycle | 343d ▼5.2% | 362d ▲4.9% | 345d ▼12.4% | 394d ▼22.3% | 507d ▼5.9% | 539d ▲36.5% | 395d ▼3.7% | 410d ▲59.5% | 257d ▲86.2% | 138d |
| Working Capital Days | 163d ▲7.9% | 151d ▲0.0% | 151d ▼23.7% | 198d ▼22.7% | 256d ▲4.1% | 246d ▼16.6% | 295d ▲42.5% | 207d ▼3.7% | 215d ▲202.8% | 71d |
| ROCE | 17.0% ▼48.5% | 33.0% ▲10.0% | 30.0% ▲66.7% | 18.0% ▲350.0% | 4.0% ▼69.2% | 13.0% ▼7.1% | 14.0% ▼39.1% | 23.0% ▼34.3% | 35.0% ▼10.3% | 39.0% |
Source: Screener.in · Lower days = better efficiency
Related Analysis
Frequently Asked Questions
What is Natco Pharma Limited share price today?▾
Natco Pharma Limited (NATCOPHARM) is currently trading at ₹961.9 on NSE, up 1.18% as of the last market session. Prices update daily after market close on MarketNetra.
Is Natco Pharma Limited available in F&O (Futures & Options)?▾
Yes, Natco Pharma Limited (NATCOPHARM) is part of the NSE F&O segment with a lot size of 1 shares. Options are available with monthly expiry contracts. You can track the full option chain and OI analysis on MarketNetra.
What is Natco Pharma Limited 52-week high and low?▾
Natco Pharma Limited's 52-week high is ₹1,227 and the 52-week low is ₹789. The current price of ₹961.9 is 21.6% below the 52W high.
What is Natco Pharma Limited P/E ratio?▾
Natco Pharma Limited's current P/E ratio is 11.9. This indicates the market is paying ₹11.9 for every ₹1 of earnings. Compare this to the sector average to assess relative valuation.
How to trade Natco Pharma Limited options?▾
Natco Pharma Limited options are traded on NSE with monthly expiry contracts (lot size: 1 shares). To trade NATCOPHARM options: select your expiry on the option chain page, identify key OI strikes, check the PCR and buildup type on OI analysis, and review FII/DII flows for institutional sentiment before taking a position.